Immobizyme platform for enzyme recycling in sweetener production
The ImmobiZyme™ platform offers a cost-effective enzyme immobilization solution for starch conversion in sweetener production, enhancing enzyme stability and processing efficiency. It promises significant economic benefits by enabling enzyme recycling and reducing post-processing expenses.
Overview
The ImmobiZyme™ platform, developed by Guild BioSciences, revolutionizes enzyme recycling in industrial sweetener production. By immobilizing enzymes onto safe, organic materials, this technology enhances enzyme stability, simplifies enzyme separation from products, and reduces post-processing costs. Its application in starch conversion processes, such as saccharifying corn starch, promises substantial economic benefits through increased enzyme reuse and efficiency.
Technical specifications
Key features:
- Enhanced stability and reusability: Immobilized enzymes demonstrate over 400 hours of continuous activity with high material recovery rates and no enzyme leaching.
- Cost-effective: Utilizes low-cost organic materials for enzyme binding, minimizing production and disposal costs.
- Versatile application: Suitable for sequential enzyme applications, improving processing efficiency across various industrial processes.
- Scalable: Capable of being scaled from lab to industrial levels, ensuring adaptability to production needs.
Technology readiness level
The ImmobiZyme™ platform is currently at Technology Readiness Level 5, having been validated in lab-scale reactors and progressing towards pilot-scale evaluation. Collaborative efforts are underway to further define parameters and evaluate performance models, with plans for industrial-scale production in the future.
About Guild Associates, Inc. (DBA Guild BioSciences)
Guild BioSciences (GBS) is a specialized bioscience research and development division of Guild Associates, Inc., a company with over three decades of experience in chemical defense, military systems, and industrial technologies. GBS focuses on the creation and commercialization of innovative biological solutions, including the proprietary ImmobiZyme enzyme immobilization technology and advanced biosensors. The division leverages its multidisciplinary engineering and production support from its parent organization to transition research into practical applications. Its facilities in Dublin, Ohio, and Charleston, South Carolina, are equipped with BioSafety Level 2 laboratories and pilot-scale fermentation capabilities, allowing the team to manage projects from initial research through to manufacturing.
Serving diverse sectors including military, health, food, and environmental markets, Guild BioSciences provides expertise in pathogen detection and refined bioprocessing. The division has successfully demonstrated its reporter phage technology, such as LumiPhage, for the rapid detection of bioterrorism agents like anthrax and plague in various sample types. By operating as an agile business unit, GBS engages in government-funded programs, corporate partnerships, and internal product development. Its commitment to research integrity and business viability is supported by a portfolio of international patents and a collaborative team of scientists dedicated to solving complex technical challenges.
delivered to your inbox.